Literature DB >> 11076105

Hyperparathyroidism and dialysis vintage.

G M Chertow1, M Plone, M A Dillon, S K Burke, E Slatopolsky.   

Abstract

BACKGROUND: Secondary hyperparathyroidism and its effects on bone and viscera are among the most important complications of end-stage renal disease. Despite its ubiquity, little is known about the treated natural history of the disorder.
METHODS: We assembled a cohort of 310 patients with endstage renal disease on hemodialysis who were participants in one of four clinical trials of the phosphate binder sevelamer. Baseline parathyroid hormone levels were collected, and the relation between dialysis vintage and other clinical variables with parathyroid hormone were described.
RESULTS: There was a direct relation between dialysis vintage and the severity of hyperparathyroidism. Other variables that were significantly associated with PTH on univariate analysis included age, African American race, Kt/V, and the serum concentrations of calcium, phosphate, and bicarbonate. Multivariable linear regression analysis yielded three significant predictors of PTH: calcium, phosphorus, and vintage (5.8% (4.0-7.5%) expected increase in PTH per year of vintage). The model R2 was 0.22.
CONCLUSION: Dialysis vintage is a key determinant of the severity of secondary hyperparathyroidism. Vintage and certain laboratory variables should be considered in the evaluation of therapies aimed at modifying the treated natural history of this disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076105

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

1.  Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

Authors:  Francesca Tentori; Mia Wang; Brian A Bieber; Angelo Karaboyas; Yun Li; Stefan H Jacobson; Vittorio E Andreucci; Masafumi Fukagawa; Luc Frimat; David C Mendelssohn; Friedrich K Port; Ronald L Pisoni; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

2.  The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients.

Authors:  Francesca Tentori; Lindsay Zepel; Douglas S Fuller; Mia Wang; Brian A Bieber; Bruce M Robinson; Ronald L Pisoni
Journal:  Am J Kidney Dis       Date:  2015-09       Impact factor: 8.860

3.  Confounded complexity: vitamin d, parathyroid hormone, and metabolic syndrome in peritoneal dialysis.

Authors:  Timothy Ellam
Journal:  Perit Dial Int       Date:  2014-06       Impact factor: 1.756

4.  Medication burden in CKD-5D: impact of dialysis modality and setting.

Authors:  Kathrine Parker; Milind Nikam; Anuradha Jayanti; Sandip Mitra
Journal:  Clin Kidney J       Date:  2014-09-11

5.  Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?

Authors:  Jacques Rottembourg; Fabrice Menegaux
Journal:  Clin Kidney J       Date:  2018-07-23

6.  Sagliker syndrome: A case report of a rare manifestation of uncontrolled secondary hyperparathyroidism in chronic renal failure.

Authors:  Yu Yu; Chen-Fang Zhu; Xiao Fu; Hua Xu
Journal:  World J Clin Cases       Date:  2019-11-26       Impact factor: 1.337

7.  Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial.

Authors:  Lin Liu; Dongsheng Hong; Kuifen Ma; Bin Wu; Xiaoyang Lu
Journal:  BMJ Open       Date:  2020-08-04       Impact factor: 2.692

8.  Cephalometric craniofacial features of patients with Sagliker syndrome: a primary analysis of our experience.

Authors:  Jiao-Ping Mi; Peng He; Kai Shi; Shao-Yan Feng; Xian-Zhen Chen; Qing-Qing He; Ming-Yue Zhao; Ping-Jiang Ge; Yun-Ping Fan
Journal:  Ann Transl Med       Date:  2021-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.